Eisai And Merck & Co Supercharge Lenvima's Potential
A global collaboration potentially valued at nearly $6bn will see Eisai's oral tyrosine kinase inhibitor lenvatinib being evaluated in combination with Keytruda in multiple cancer types and indications.
You may also be interested in...
The company will depend on Keytruda for growth after spinning out some franchises, but executives argued during its Q4 earnings call that there will be much more to Merck than the cancer blockbuster.
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.